ArticlePloS one2025
Malaria in travelers and local populations: Comprehensive study of incidence patterns and origin-based classification in Saudi Arabia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The persistent threat of malaria in Bishoftu Town: twelve-year trends and their implications for Addis Ababa.BMC research notes · 2026Article
- Clinical Characteristics and Outcomes of Malaria Patients in the Aseer Region, Saudi Arabia: A Retrospective Study (2022-2025).Tropical medicine and infectious disease · 2026Article
- Malaria: Examining Persistence at the Margins of Endemicity over 15 Years in Saudi Arabia.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria continues to pose a significant public health threat in the Kingdom of Saudi Arabia (KSA), despite ongoing control efforts. Most malaria cases in the KSA are associated with travelers arriving from malaria-endemic regions. The rationale for studying malaria in the KSA stems from the country's goal to eliminate the disease and address the increased risk of imported cases, which is heightened by substantial migration and religious tourism.
methodsThis study aimed to assess the origins of malaria cases, the relative contribution of the different Plasmodium species involved, and the incidence rates across different age groups in the KSA. The Ministry of Health collected data on malaria cases in 13 administrative regions from January 2022 to December 2023. The chi-square test was used to analyze the data and determine the overall parameters and the rate of slide positivity.
resultsThe findings indicated that "imported" malaria cases were the predominant type of disease in the KSA. Out of 1,453,451 febrile cases examined, 0.7% (10,779) were positive across the 13 regions. In 2022, 688,629 cases were examined, with 0.9% (6,460) being positive. In 2023, 764,822 cases were examined, with 0.6% (4,319) being positive. Among these regions, Jazan exhibited the highest incidence rates (59%), followed by Makkah (20%), with a statistically significant difference (P = 0.046) between the regions. Malaria incidence was higher in patients aged ≥15 years. This study found significant variations (P = 0.002) in malaria incidence rates among different Plasmodium species. Plasmodium falciparum exhibited the highest rate at 63.5%, followed by P. vivax-P. ovale at 33%, P. malariae at 0.5%, and mixed infections where more than one species is involved at 3%.
conclusionDuring the study period, imported malaria was the major type of malaria, especially in the Jazan region and Makkah. The highest incidence was caused by P. falciparum. These findings indicate the need for targeted interventions and public health strategies to mitigate the "imported" malaria burden, particularly among travelers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.